Trial Profile
Non-Interventional Study to Investigate the Effectiveness, Safety and Utilization of Vismodegib on Locally Advanced Basal Cell Carcinoma Under Real World Conditions (NIELS)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Aug 2021
Price :
$35
*
At a glance
- Drugs Vismodegib (Primary)
- Indications Basal cell cancer
- Focus Therapeutic Use
- Acronyms NIELS
- Sponsors Roche
- 01 Aug 2021 Results (n=66) assessing effectiveness with a special focus on duration of response (DOR), safety and utilization of vismodegib for treatment of locally advanced basal cell carcinoma, in daily practice in Germany, published in the Journal of the European Academy of Dermatology and Venereology.
- 10 May 2019 Status changed from active, no longer recruiting to completed.
- 02 Oct 2017 Planned End Date changed from 1 Mar 2019 to 31 Mar 2019.